Clinical Trial

A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.
Protocol Amendment History 2 changes
notable Enrollment increased: 30 -> 40 participants 2026-08-13
notable Trial sites expanded: 8 -> 11 locations 2026-08-13
Trial Details
NCT Number NCT07459543
Lead Sponsor Bristol-Myers Squibb
Conditions Unresectable Melanoma, Metastatic Melanoma
Enrollment 40 participants
Start Date 2026-11-15
Primary Completion 2029-05-26 (estimated)
Study Completion 2029-05-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-12